More than $1.5 billion in cash flooded into four IPOs offerings for China-based drug developers this year. These were just the first. The China biotech IPO opening was — and will continue to be — a big ongoing story. In April, the Hong Kong Stock Exchange relaxed rules allowing public stock investment in pre-revenue (development-stage) biotech companies. In July, the...Read More
Timmerman Report Gives You Consistent In-Depth Reporting on Biotechnology. Get Your Edge.